Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients
with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose
is to establish proof of principle that ivosidenib is well-tolerated and potentially
efficacious in improving blood count abnormalities in these patients.